Univest
Univest
  • Markets

3 Decorative Paints Company, Customer Services Outsourcing Firm and Pharmaceuticals Maker Stocks With a Strong Future Roadmap: Berger Paints India, Firstsource Solutions and Lupin

  • November 18, 2026
  • Posted by: Lakshit Sharma
  • Category: Best Stocks
No Comments
3 Decorative Paints Company, Customer Services Outsourcing Firm and Pharmaceuticals Maker Stocks With a Strong Future Roadmap: Berger Paints India, Firstsource Solutions and Lupin

Berger Paints India, Firstsource Solutions and Lupin: ROE of 16.3% to 23.8% and FY22 to FY26 revenue CAGR of 8.0% to 15.0%. Prices as of 17 Nov 2026.

Quick Answer

The three wall paint, call centre and drug stocks to watch are Berger Paints India, Firstsource Solutions and Lupin. Their return on equity ranges from 16.3% to 23.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.0% to 15.0%. Lupin leads on both return on equity at 23.8% and revenue growth at 15.0% a year. Prices are based on the 17 November 2026 close, and this article is educational, not investment advice.

Wall paint, call centre and drug stocks offer a focused view of a sector where demand keeps widening. Berger Paints India, Firstsource Solutions and Lupin cover a decorative paints company, a customer services outsourcing firm and a pharmaceuticals maker.

This list covers three wall paint, call centre and drug stocks with complete current figures: Berger Paints India, Firstsource Solutions and Lupin. Every figure comes from the latest reported financials and the 17 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • What Are Wall Paint, Call Centre and Drug Stocks?
  • Wall Paint, Call Centre and Drug Stocks at a Glance
  • Why Do Wall Paint, Call Centre and Drug Stocks Have a Strong Roadmap in India?
  • Why Berger Paints India Features Among These Wall Paint, Call Centre and Drug Stocks
  • Why Firstsource Solutions Features Among These Wall Paint, Call Centre and Drug Stocks
  • Why Lupin Features Among These Wall Paint, Call Centre and Drug Stocks
  • Berger Paints India vs Firstsource Solutions vs Lupin on Key Financials
  • Key Risks to Check Before Investing in Wall Paint, Call Centre and Drug Stocks
  • Final Thoughts on Wall Paint, Call Centre and Drug Stocks
    • What are wall paint, call centre and drug stocks?
    • Which wall paint, call centre and drug stocks are covered in this list?
    • Why do wall paint, call centre and drug stocks have a strong future roadmap in India?
    • How has Berger Paints India performed financially?
    • How has Firstsource Solutions performed financially?
    • How has Lupin performed financially?
    • What risks should investors check before buying wall paint, call centre and drug stocks?
    • Is this list of wall paint, call centre and drug stocks investment advice?

What Are Wall Paint, Call Centre and Drug Stocks?

Wall paint, call centre and drug stocks are listed companies that make decorative paints and industrial coatings for homes and factories, provide customer service and back office outsourcing to global firms, and make medicines for India, the United States and other markets. Their earnings depend on housing activity, outsourcing contracts and medicine demand.

Wall Paint, Call Centre and Drug Stocks at a Glance

Company CMP (Rs) Market Cap (Rs Cr) P/E Industry P/E ROE (%) D/E
Berger Paints India 478.9 54,785 45.0 42.6 16.3 0.09
Firstsource Solutions 286.2 19,489 29.1 17.5 17.1 0.67
Lupin 1,950 89,343 16.1 36.0 23.8 0.29

On valuation, Lupin trades at a P/E below the industry P/E, while Berger Paints India and Firstsource Solutions trade above it, which reflects the growth the market already expects. Readers comparing wall paint, call centre and drug stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in wall paint, call centre and drug stocks can use the coming numbers to test whether growth is holding.

Why Do Wall Paint, Call Centre and Drug Stocks Have a Strong Roadmap in India?

Wall paint, call centre and drug stocks have a strong roadmap in India because strong demand for new and repainted homes, rising outsourcing of customer work and steady demand for medicines keep widening the market for these companies.

  • Paints. Homes need regular painting.
  • Customer services. Global firms outsource service work.
  • Pharmaceuticals. Patients need dependable medicines.

Why Berger Paints India Features Among These Wall Paint, Call Centre and Drug Stocks

Among the wall paint, call centre and drug stocks on this list, Berger Paints India is a leading paint maker with decorative, industrial and protective coatings, selling through a wide dealer network across India and in select overseas markets.

Revenue rose from Rs 8,826 crore in FY22 to Rs 11,987 crore in FY26, a compound annual growth rate of 8.0%. Net profit grew from Rs 833 crore in FY22 to Rs 1,128 crore in FY26, which works out to a compound annual growth rate of 7.9%.

In the June 2026 quarter, revenue grew 12.2% year on year to Rs 3,623 crore, while net profit rose 28.6% to Rs 405 crore. The company has a return on equity of 16.3%, a debt to equity ratio of 0.09 and a market capitalisation of Rs 54,785 crore. The stock trades at a P/E of 45.0, above the industry P/E of 42.6.

Roadmap: The company is expanding capacity and its dealer reach while adding home improvement and waterproofing products. Housing demand and repainting cycles support steady volumes.

What to watch: Track volume growth, new capacity and input costs.

Why Firstsource Solutions Features Among These Wall Paint, Call Centre and Drug Stocks

Among the decorative coatings, customer service outsourcing and pharma shares on this list, Firstsource Solutions, an RPG group company, is a business process management firm serving banks, healthcare payers and providers, and other clients, mainly in the United States and the United Kingdom.

In the June 2026 quarter, revenue grew 22.8% year on year to Rs 2,731 crore. Revenue rose from Rs 5,922 crore in FY22 to Rs 9,564 crore in FY26, a compound annual growth rate of 12.7%.

Net profit grew from Rs 537 crore in FY22 to Rs 674 crore in FY26, which works out to a compound annual growth rate of 5.9%. The company has a return on equity of 17.1%, a debt to equity ratio of 0.67 and a market capitalisation of Rs 19,489 crore. The stock trades at a P/E of 29.1, above the industry P/E of 17.5.

Roadmap: It is growing in healthcare and mortgage services, pursuing larger deals and using artificial intelligence to improve productivity. Longer contracts with large clients give it visibility on revenue.

What to watch: Follow contract wins in healthcare and the pace of new technology investments.

Why Lupin Features Among These Wall Paint, Call Centre and Drug Stocks

Among the three companies on this list, Lupin is a Mumbai-headquartered global pharmaceutical company with a presence in branded generics in India, complex generics and specialty products in the United States, and active ingredients, with strength in respiratory, cardiovascular, anti-diabetic and anti-infective therapies.

The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P/E of 16.1, below the industry P/E of 36.0.

Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%. In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore.

Roadmap: The company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.

What to watch: Track key launches in the United States, especially in inhalation and complex injectables, and the growth of the India branded business.

Berger Paints India vs Firstsource Solutions vs Lupin on Key Financials

The table below sets the three wall paint, call centre and drug stocks side by side on revenue, profit and margin, using reported figures.

Company FY22 Revenue (Rs Cr) FY26 Revenue (Rs Cr) Revenue CAGR (FY22-FY26) FY26 Net Profit (Rs Cr) FY26 Net Margin
Berger Paints India 8,826 11,987 8.0% 1,128 9.4%
Firstsource Solutions 5,922 9,564 12.7% 674 7.1%
Lupin 16,616 29,039 15.0% 5,355 18.4%

Lupin posts the highest return on equity in this group at 23.8%. Lupin combines the largest FY26 revenue at Rs 29,039 crore with the fastest revenue growth, a 15.0% compound annual rate. A useful habit with wall paint, call centre and drug stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several home paints, BPO services and generic medicines stocks instead of one name, which keeps a single result from deciding the outcome.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Company Q1 FY26 Revenue (Rs Cr) Q1 FY27 Revenue (Rs Cr) Year-on-Year Growth
Berger Paints India 3,229 3,623 12.2%
Firstsource Solutions 2,224 2,731 22.8%
Lupin 6,347 8,407 32.5%

Key Risks to Check Before Investing in Wall Paint, Call Centre and Drug Stocks

Every theme carries risks that deserve a check before any decision. For these wall paint, call centre and drug stocks, the main points are: Long-term decorative coatings, customer service outsourcing and pharma shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

  • Housing cycles. Real estate and building demand can vary with rates and sentiment.
  • Client spending. Technology budgets can vary with global conditions.
  • Regulatory approvals. Plant inspections and approvals can affect supplies.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter wall paint, call centre and drug stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Wall Paint, Call Centre and Drug Stocks

Wall paint, call centre and drug stocks reward patient research into demand, execution and financial strength. Berger Paints India, Firstsource Solutions and Lupin each have a clear plan to grow. Based on the 17 November 2026 close, Berger Paints India trades at Rs 478.9, Firstsource Solutions at Rs 286.2 and Lupin at Rs 1,950. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these wall paint, call centre and drug stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track wall paint, call centre and drug stocks, set price alerts and get research-backed stock ideas.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

What are wall paint, call centre and drug stocks?

Ans. Wall paint, call centre and drug stocks are listed companies that make decorative paints and industrial coatings for homes and factories, provide customer service and back office outsourcing to global firms, and make medicines for India, the United States and other markets. Their earnings depend on housing activity, outsourcing contracts and medicine demand. This list looks at three of them, Berger Paints India, Firstsource Solutions and Lupin, using reported FY22 to FY26 financials and the 17 November 2026 closing prices.

Which wall paint, call centre and drug stocks are covered in this list?

Ans. This list covers Berger Paints India, Firstsource Solutions and Lupin. Based on the 17 November 2026 close, Berger Paints India traded at Rs 478.9, Firstsource Solutions at Rs 286.2 and Lupin at Rs 1,950. Their return on equity ranges from 16.3% to 23.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.0% to 15.0%.

Why do wall paint, call centre and drug stocks have a strong future roadmap in India?

Ans. Wall paint, call centre and drug stocks have a strong roadmap in India because strong demand for new and repainted homes, rising outsourcing of customer work and steady demand for medicines keep widening the market for these companies. The main drivers are as follows. Paints. Homes need regular painting. Customer services. Global firms outsource service work. Pharmaceuticals. Patients need dependable medicines. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Berger Paints India performed financially?

Ans. Revenue rose from Rs 8,826 crore in FY22 to Rs 11,987 crore in FY26, a compound annual growth rate of 8.0%. Net profit grew from Rs 833 crore in FY22 to Rs 1,128 crore in FY26, which works out to a compound annual growth rate of 7.9%. In the June 2026 quarter, revenue grew 12.2% year on year to Rs 3,623 crore, while net profit rose 28.6% to Rs 405 crore. The company has a return on equity of 16.3%, a debt to equity ratio of 0.09 and a market capitalisation of Rs 54,785 crore. The stock trades at a P/E of 45.0, above the industry P/E of 42.6. Looking ahead, the company is expanding capacity and its dealer reach while adding home improvement and waterproofing products. Housing demand and repainting cycles support steady volumes.

How has Firstsource Solutions performed financially?

Ans. Revenue rose from Rs 5,922 crore in FY22 to Rs 9,564 crore in FY26, a compound annual growth rate of 12.7%. Net profit grew from Rs 537 crore in FY22 to Rs 674 crore in FY26, which works out to a compound annual growth rate of 5.9%. In the June 2026 quarter, revenue grew 22.8% year on year to Rs 2,731 crore. The company has a return on equity of 17.1%, a debt to equity ratio of 0.67 and a market capitalisation of Rs 19,489 crore. The stock trades at a P/E of 29.1, above the industry P/E of 17.5. Looking ahead, it is growing in healthcare and mortgage services, pursuing larger deals and using artificial intelligence to improve productivity. Longer contracts with large clients give it visibility on revenue.

How has Lupin performed financially?

Ans. Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%. In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore. The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P/E of 16.1, below the industry P/E of 36.0. Looking ahead, the company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.

What risks should investors check before buying wall paint, call centre and drug stocks?

Ans. Investors should check a few risks before buying wall paint, call centre and drug stocks. Housing cycles. Real estate and building demand can vary with rates and sentiment. Client spending. Technology budgets can vary with global conditions. Regulatory approvals. Plant inspections and approvals can affect supplies. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of wall paint, call centre and drug stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 17 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.



Berger Paints India Best Stocks BPO services and generic medicines stocks call centre and drug stocks customer service outsourcing and pharma shares decorative coatings Firstsource Solutions home paints Lupin wall paint

Leave a Reply Cancel reply